Gavin MacBeath - 18 Jan 2022 Form 4 Insider Report for TScan Therapeutics, Inc. (TCRX)

Role
Chief Scientific Officer
Signature
/s/ Gavin MacBeath
Issuer symbol
TCRX
Transactions as of
18 Jan 2022
Transactions value $
$0
Form type
4
Filing time
20 Jan 2022, 15:26:58
Previous filing
22 Sep 2021
Next filing
27 Jul 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TCRX Stock Option (Right to Buy) Award $0 +140K $0.00 140K 18 Jan 2022 Voting Common Stock 140K $4.85 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option vest over 4 years of service following January 18, 2022, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter.